These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22292554)

  • 1. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola.
    Moore WJ; Richard D; Thorarensen A
    Expert Opin Ther Pat; 2010 Dec; 20(12):1703-22. PubMed ID: 21073366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deal watch: high hopes for oral SYK inhibitor in rheumatoid arthritis.
    Flight MH
    Nat Rev Drug Discov; 2012 Jan; 11(1):10. PubMed ID: 22212667
    [No Abstract]   [Full Text] [Related]  

  • 6. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Otón T; Silva-Fernández L; Andreu JL
    N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
    [No Abstract]   [Full Text] [Related]  

  • 8. [Syk inhibitors].
    Kimura Y; Chihara K; Takeuchi K; Sada K
    Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Okamoto H; Kobayashi A
    N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
    Norman P
    Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
    Bajpai M; Chopra P; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2008 May; 17(5):641-59. PubMed ID: 18447591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
    Boers M
    Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
    [No Abstract]   [Full Text] [Related]  

  • 17. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Getting Syk: spleen tyrosine kinase as a therapeutic target.
    Geahlen RL
    Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing the Syk through kinase inhibitors.
    Rivera J; Colbert RA
    N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.